Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation-Reference-Cited by-同舟云学术

Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation

Published:2014-06-05 Issue:23 Volume:123 Page:3664-3671
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Armand Philippe¹,Kim Haesook T.²,Logan Brent R.³⁴,Wang Zhiwei³,Alyea Edwin P.¹,Kalaycio Matt E.⁵,Maziarz Richard T.⁶,Antin Joseph H.¹,Soiffer Robert J.¹,Weisdorf Daniel J.⁷,Rizzo J. Douglas³,Horowitz Mary M.³,Saber Wael³

Affiliation:

1. Department of Medical Oncology and

2. Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston MA;

3. Center for International Blood and Marrow Transplant Research, Department of Medicine and

4. Division of Biostatistics, Institute for Health and Society, Medical College of Wisconsin, Milwaukee, WI;

5. Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic, Cleveland, OH;

6. Center for Hematologic Malignancies, Knight Cancer Institute, Oregon Health & Science University, Portland, OR; and

7. Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN

Abstract

Key Points The DRI successfully stratified patients in a very large allogeneic transplantation registry cohort. The DRI was refined by using this cohort to build a more inclusive and conditioning intensity–independent index.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/123/23/3664/1378059/3664.pdf

Reference17 articles.

1. Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: revised definitions to predict survival.;Weisdorf;Biol Blood Marrow Transplant,2008

2. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.;Sorror;Blood,2005

3. A disease risk index for patients undergoing allogeneic stem cell transplantation.;Armand;Blood,2012

4. Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte antigen mismatch.;Slack;Biol Blood Marrow Transplant,2013

5. Outcome and prognostic factors for patients who relapse after allogeneic hematopoietic stem cell transplantation.;Thanarajasingam;Biol Blood Marrow Transplant,2013

Cited by 761 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recipient IL-17A polymorphism rs2275913 is associated with acute graft-versus-host disease after single-unit cord blood transplantation;Transplant Immunology;2024-10

2. Impact of spliceosome mutation on outcomes of myelodysplastic syndrome and chronic myelomonocytic leukemia patients undergoing allogeneic hematopoietic cell transplantation;Leukemia Research;2024-10

3. WT1 Expression Is Associated with Poor Overall Survival after Azacytidine and DLI in a Cohort of Adult AML and MDS Patients;Cancers;2024-09-04

4. Fludarabine Melphalan, Reduced-dose Busulfan Versus Fludarabine, Melphalan, Full-dose Busulfan in Patients Receiving Cord Blood Transplantation;Transplantation Proceedings;2024-09

5. Levels of C-reactive protein and body temperature elevation during neutropenia predict engraftment and non-relapse mortality for unrelated single-unit cord blood transplantation in adults;Transplantation and Cellular Therapy;2024-09